Introduction
============

Thymic epithelial tumors (TET) are relatively rare mediastinal neoplasms.[@b1-ott-9-4527] Surgery is the standard treatment for patients at an early stage, and complete resection is the most important prognostic factor for survival.[@b2-ott-9-4527] However, recurrence or metastasis is a big issue in clinical practice.[@b3-ott-9-4527] For patients with distant metastasis, salvage chemotherapy plays an important role in the treatment of thymic malignancies.[@b4-ott-9-4527],[@b5-ott-9-4527] No definitive chemotherapeutic regimen has been established due to its rarity. The regimens of cisplatin, vincristine, doxorubicin, and etoposide; cisplatin and paclitaxel; and etoposide, ifosfamide, and cisplatin are recommended as first-line treatment with a progression-free survival (PFS) within 8 months.[@b6-ott-9-4527]--[@b8-ott-9-4527] Most of the patients would progress after first-line chemotherapy. For these patients, standard regimens have not been identified.

Pemetrexed is a pyrrolopyrimidine antifolate, which inhibits thymidylate synthetase, glycinamide ribonucleotide formyltransferase, and dihydrofolate reductase. Pemetrexed is widely used for the treatment of nonsquamous non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma. The results of randomized studies demonstrated that pemetrexed was less toxic and more effective in NSCLC treatment.[@b9-ott-9-4527]--[@b11-ott-9-4527] However, the efficacy and toxicity data of pemetrexed as salvage therapy were limited in TET. In addition, thymidylate synthetase (TS) level was significantly associated with clinical efficacy of pemetrexed-based chemotherapy in NSCLC patients.[@b12-ott-9-4527],[@b13-ott-9-4527] However, the association between the TS level and efficacy of pemetrexed-based regimen in TET is unclear.

In this study, we conducted a retrospective study to evaluate the efficacy of pemetrexed-based regimen in advanced TET as salvage chemotherapy and further to detect the relationship between TS level and clinical efficacy of this regimen.

Materials and methods
=====================

Patient eligibility
-------------------

Data from 22 patients who received pemetrexed-based treatment as second- or further-line chemotherapy regimen with advanced TET were collected in Zhejiang Cancer Hospital from 2006 to 2014. All patients met the following criteria: 1) histological diagnosis of TET according to the histopathological criteria proposed by the World Health Organization 2004 version; 2) Masaoka criteria stage of IVa or IVb; 3) had progressed from prior chemotherapy regimens; 4) without any local treatment such as radiotherapy or interventional therapy during the time of pemetrexed-based therapy. The Ethics Committee of Zhejiang Cancer Hospital approved this study. All patients provided written informed consent.

Efficacy evaluation
-------------------

Clinical efficacy was assessed every two cycles, or evaluated early when significant signs of progression appeared. The Response Evaluation Criteria in Solid Tumors (RECIST 1.1) was used to evaluate tumor responses.

Measurement of TS mRNA
----------------------

Tumor cells were collected from formalin-fixated, paraffin-embedded tissue samples. Total RNA was extracted using a commercial method (Amory, Xiamen, People's Republic of China), and cDNA was generated with oligo-dT and random primers. Real-time quantitative polymerase chain reaction analysis was performed in triplicate per sample. The relative amount of TS mRNA in a sample was determined by comparing the threshold cycle with a standard curve. The details of this process have been published in previous studies.[@b14-ott-9-4527],[@b15-ott-9-4527]

Follow-up and statistical analysis
----------------------------------

The last follow-up time was March 31, 2015 and median follow-up period was 37.5 months (5.0--62). The follow-up rate was 100%. Overall survival (OS) was defined as the time from the first day of diagnosis as advanced issues to death or last follow-up time. PFS encompassed the time from the first cycle of pemetrexed-based treatment to documented progression or death from any cause. The survival curves were calculated according to the method of Kaplan--Meier. Statistical analysis was performed using SPSS version 18.0 (SPSS Inc., Chicago, IL).

Results
=======

Patients' characteristics
-------------------------

Twenty-two patients were included in this study. There were ten males and 12 females with median age of 48.5 years old. Eight patients had thymoma and 14 had thymic carcinoma. Twelve patients had a performance status (PS) of 0--1 and ten had a PS of 2. Eighteen patients received single pemetrexed and four received pemetrexed/carboplatin therapy. The first-line regimens of the 22 patients comprised cyclophosphamide + doxorubicin + cisplatin, n=7; paclitaxel + carboplatin, n=7; ifosfamide + cisplatin + etoposide, n=4; and etoposide + cisplatin, n=4. Patients' characteristics are listed in [Table 1](#t1-ott-9-4527){ref-type="table"}.

Response data and survival analysis
-----------------------------------

The median number of pemetrexed chemotherapy cycles was four (range, 1--6). Of the 22 patients, partial response was confirmed in five and ten showed stable disease, representing a response rate of 22.7% and disease control rate of 68.2%. The median PFS was 4.5 months (95% confidence interval \[CI\]: 3.1--5.9) ([Figure 1](#f1-ott-9-4527){ref-type="fig"}). There was no significant association between PFS and sex (*P*=0.18), age (*P*=0.29), stage (*P*=0.74), and chemotherapy regimen (*P*=0.69). However, a trend of longer PFS existed in thymoma (*P*=0.083) and PS of 0--1 (*P*=0.053) ([Table 2](#t2-ott-9-4527){ref-type="table"}).

The median OS was 34.9 months (95% CI: 31.3--38.4) ([Figure 2](#f2-ott-9-4527){ref-type="fig"}). No OS difference was according to sex (*P*=0.18), age (*P*=0.29), stage (*P*=0.74), and chemotherapy regimen (*P*=0.85). The OS was longer in patients with thymoma than thymic carcinoma (*P*=0.039) ([Table 2](#t2-ott-9-4527){ref-type="table"}).

Thymidylate synthetase mRNA level
---------------------------------

The median TS mRNA levels in all patients were 380.5±326.0×10^−4^. TS mRNA levels in patients with disease control (partial response + stable disease) under pemetrexed treatment were lower than those with progressive disease (268.0±160.5×10^−4^ vs 567.0±445.0×10^−4^, *P*=0.065) ([Figure 3](#f3-ott-9-4527){ref-type="fig"}).

Discussion
==========

Our results demonstrated that some patients with advanced TET may benefit from pemetrexed-based regimen and the clinical efficacy of pemetrexed in TET was associated with TS mRNA level. To our knowledge, we represent the largest amount of data to assess the efficacy of pemetrexed-based regimen as salvage chemotherapy in TET.

Anthracycline- and platinum-based regimens are now recommended as first-line treatment in the National Comprehensive Cancer Network (NCCN) guidelines.[@b16-ott-9-4527] For patients with TET who have progressed after chemotherapy, no standard treatment is established currently. All of the previous regimens were based on case reports or series with limited numbers. The regimens included S-1, gemcitabine, irinotecan, and docetaxel,[@b17-ott-9-4527]--[@b20-ott-9-4527] and the efficacy of these regimens varied from 3 to 18 months.

Pemetrexed-based chemotherapy is widely used in NSCLC patients and demonstrated better efficacy and lower toxicity than other third-generation drugs.[@b9-ott-9-4527]--[@b11-ott-9-4527] However, little is known about the efficacy of pemetrexed in TET due to its rarity. Liang et al reported 16 patients with TET (six with thymoma and ten with thymic carcinoma) and demonstrated that the median PFS was different in thymoma (13.8 months) and thymic carcinoma (6.5 months) with pemetrexed-based treatment.[@b21-ott-9-4527] Our results showed that the median PFS was 4.5 months with a regimen of pemetrexed-based treatment. The reason for shorter PFS in this study may be due to more patients with poor PS and further-line treatment in the current cohort.

Previous studies demonstrated that negative or low level TS expression benefited more from pemetrexed-based chemotherapy than positive or high levels of TS in NSCLC patients.[@b12-ott-9-4527],[@b13-ott-9-4527] Although some studies reported the expression of TS level in thymic malignancies, no association between TS level and pemetrexed's efficacy has been investigated.[@b22-ott-9-4527],[@b23-ott-9-4527] We examined the TS mRNA level in all of our 22 patients. The results demonstrated that patients with lower TS mRNA level benefited more from pemetrexed-based regimen. Our data indicated that TS mRNA level enables the selection of pemetrexed-based regimen options in TET patients.

Some of the limitations of our study were related to its retrospective design with an enrollment of only 22 patients. However, given the limited literature available, our study can also be meaningful for clinical practice.

In summary, our results suggest that pemetrexed-based treatment is effective as a salvage chemotherapy for pretreated advanced TET. The TS mRNA level may be a predicting factor for the efficacy of pemetrexed-based regimen in TET.
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###### 

Clinical characteristics of 22 patients with advanced thymic epithelial tumors

  Case   Sex/age, years   Histology          Stage   PS   Line of therapy   Regimen      Response   PFS, months   OS, months
  ------ ---------------- ------------------ ------- ---- ----------------- ------------ ---------- ------------- ------------
  1      F/69             Thymic carcinoma   Iva     1    Second            PC           SD         4.0           29.5
  2      M/48             Thymic carcinoma   IVb     2    Third             Pemetrexed   SD         4.0           28.7
  3      M/55             Thymoma            IVb     1    Second            Pemetrexed   PR         7.0           32.5
  4      F/49             Thymoma            Iva     2    Second            PC           PR         9.5           37.4
  5      F/47             Thymic carcinoma   IVb     2    Third             Pemetrexed   PD         1.5           19.0
  6      M/55             Thymoma            IVb     1    Second            Pemetrexed   PR         10.5          39.0
  7      F/60             Thymic carcinoma   IVb     2    Third             PC           PD         1.2           17.0
  8      F/22             Thymic carcinoma   Iva     1    Third             Pemetrexed   SD         8.0           35.5
  9      F/70             Thymoma            IVb     2    Fourth            Pemetrexed   SD         5.5           44.0+
  10     M/65             Thymoma            IVb     1    Second            Pemetrexed   SD         6.0           35.0
  11     F/45             Thymic carcinoma   Iva     2    Fifth             Pemetrexed   PD         1.4           20.0
  12     M/27             Thymic carcinoma   IVb     2    Third             Pemetrexed   PD         1.0           15.0
  13     M/32             Thymoma            IVb     1    Fifth             Pemetrexed   SD         3.5           25.6
  14     M/39             Thymic carcinoma   Iva     2    Third             Pemetrexed   PD         2.2           23.5
  15     F/55             Thymic carcinoma   Iva     0    Fifth             PC           SD         6.0           45.8
  16     M/59             Thymic carcinoma   IVb     1    Third             Pemetrexed   SD         6.0           36.6
  17     F/45             Thymoma            IVb     0    Fourth            Pemetrexed   PD         1.2           47.4
  18     F/47             Thymic carcinoma   Iva     2    Second            Pemetrexed   PD         1.0           12.3+
  19     M/56             Thymic carcinoma   IVb     0    Fifth             Pemetrexed   SD         5.0           37.2
  20     F/43             Thymoma            IVb     2    Fourth            Pemetrexed   PR         4.5           23.6+
  21     M/44             Thymic carcinoma   Iva     0    Second            Pemetrexed   PR         6.5           32.8
  22     F/49             Thymic carcinoma   IVb     1    Fifth             Pemetrexed   SD         4.5           34.9

**Abbreviations:** PS, performance status; M, male; F, female; PC, pemetrexed/carboplatin; PFS, progression-free survival; OS, overall survival; PR, partial response; SD, stable disease; PD, progressive disease.

###### 

Univariate analysis of patients with pemetrexed-based chemotherapy

                            PFS   *P*-value   Overall survival   *P*-value
  ------------------------- ----- ----------- ------------------ -----------
  Sex                             0.39                           0.18
   Male                     5.0               32.5               
   Female                   4.0               35.5               
  Age, years                      0.17                           0.29
   \<50                     3.5               28.7               
   ≥50                      6.0               36.6               
  Histology                       0.083                          0.039
   Thymoma                  5.5               37.4               
   Thymic carcinoma         4.0               29.5               
  Performance status              0.053                          0.20
   0--1                     6.0               35.0               
   2                        1.5               23.5               
  Stage                           0.68                           0.74
   Iva                      4.0               34.9               
   Ivb                      4.5               32.8               
  Chemotherapy regimen            0.69                           0.85
   Pemetrexed               4.5               34.9               
   Pemetrexed/carboplatin   4.0               29.5               

**Abbreviation:** PFS, progression-free survival.
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